From the Research
Red light therapy (RLT) has shown promising evidence for reducing systemic inflammation, particularly when used with wavelengths between 630-850 nm for 10-20 minute sessions several times weekly, as supported by the most recent study 1. The current research suggests that RLT may help decrease inflammatory markers like C-reactive protein and pro-inflammatory cytokines when used regularly. For optimal results, consistent treatment over 4-12 weeks using medical-grade devices is recommended. RLT works by stimulating mitochondrial function and ATP production, which can modulate inflammatory pathways and enhance cellular repair mechanisms. The therapy appears to activate anti-inflammatory responses through photobiomodulation, where light energy is absorbed by cellular chromophores, particularly cytochrome c oxidase in mitochondria. Some key points to consider when using RLT for reducing systemic inflammation include:
- The importance of using medical-grade devices to ensure safety and efficacy
- The need for consistent treatment over several weeks to achieve optimal results
- The potential for RLT to be used as a complementary approach to managing chronic inflammation, although it should not replace conventional medical treatments for inflammatory diseases
- The limited but growing evidence base for RLT in reducing systemic inflammation, with more robust clinical trials needed to establish standardized protocols and confirm its effectiveness for specific inflammatory conditions, as noted in studies 2, 3, 4, 5.